Analysis of adverse events after radiotherapy for primary and metastatic prostate carcinoma in patients with oligometastasized castration resistant prostate carcinoma
10.3760/cma.j.issn.1004-4221.2018.02.012
- VernacularTitle:寡转移去势抵抗前列腺癌原发灶与转移灶放疗不良反应分析
- Author:
Hongzhen LI
1
;
Xianshu GAO
;
Xin QI
;
Shangbin QIN
;
Chen JI
;
Min ZHANG
;
Xiaoying LI
;
Qingguo WANG
;
Xiaomei LI
Author Information
1. 100034,北京大学第一医院放疗科
- Keywords:
Castration resistant prostate carcinoma/volumetric modulated arc therapy;
Oligometastasis;
Adverse event
- From:
Chinese Journal of Radiation Oncology
2018;27(2):181-184
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the adverse events in patients diagnosed with oligometastasized castration resistant prostate carcinoma (CRPC) receiving radiotherapy for the primary and metastatic prostate carcinomas.Methods Twenty patients with oligometastasized CRPC admitted to our hospital between 2011 and 2015 were treated with image-guided volumetric modulated arc therapy (VMAT).The dose for prostate+ seminal vesicle was 76 Gy/38 f,46 Gy/23 f for the pelvic lymph node and the median dose for the metastatic lesions was 60 Gy (52-66)/23 f.Relevant clinical data and adverse events were analyzed.Results All patients completed the radiotherapy.Only 1 patient showed grade Ⅲ urinary obstruction and received catheterization.In terms of acute adverse events of ≥ grade Ⅱ,urinary tract was observed in 4 cases (20％),rectum in 2 (10％) and blood system in 2(10％).The rectal V50 was correlated with acute adverse events of ≥ grade Ⅱ.The median follow-up time was 24.2 months.No patient suffered from late adverse events of ≥ grade Ⅱ.All cases showed a decline in the level of prostate specific antigen (PSA) after radiotherapy.The median PSA reduction rate was 99％.Among them,16 cases (80％) had a PSA reduction rate of over 90％.Conclusions It is safe and efficacious to perform radical dosage radiotherapy for primary and metastatic prostate carcinomas in patients with oligometastasized CRPC.
